Advent Gains High-Potential ART Business Through Bharat Buy
Deal Gives Exit To Other PE Groups
With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The deal also provides an exit to two other PE funds - OrbiMed and Kotak.
You may also be interested in...
Private equity-controlled Bharat Serums and Vaccines gets go-ahead in India for COVID-19-related trials with ulinastatin, an existing sepsis therapy for which it is the leading player in the country. Management also outlines how the firm is ensuring business continuity during this challenging phase.
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
Scrip highlights the key transactions involving Indian firms in 2019. Divestments and licensing were among the prominent themes that dotted the deal landscape in the year gone by.